Circulating IL‑37 levels are elevated in patients with hypertension

Abstract

has been reported to be closely linked to vascular diseases, including atherosclerosis and aortic calcification. The present study aimed to assess the expression levels of IL-37 in patients with hypertension. Blood samples were collected from control subjects (n=20) and patients with hypertension (n=45). Subsequently, macrophages, lymphocytes and dendritic cells were individually isolated and the mRNA expression of IL-37 was measured. In addition, the circulating IL-37 levels in control subjects (n=30) and patients with hypertension (n=334) were assessed. Furthermore, all patients who were subjected to detection of circulating IL-37 underwent ambulatory blood pressure monitoring. The results suggested that the mRNA levels of IL-37 in macrophages, but not in lymphocytes and dendritic cells, isolated from patients with hypertension were markedly elevated compared with those in cells isolated from control subjects. Circulating IL-37 levels were increased in patients with hypertension compared with those in control subjects and positively correlated with systolic and diastolic blood pressure in patients with hypertension. No differences were observed between patients with dipper hypertension and patients with non-dipper hypertension. In addition, patients with hypertension with a smoking habit, type 2 diabetes mellitus and carotid atherosclerotic plaque (CAP) exhibited higher IL-37 levels. IL-37 levels were positively correlated with creatinine, C-reactive protein and homocysteine levels. Furthermore, the results of a linear regression analysis suggested that IL-37 levels were independently associated with the presence of CAP. In conclusion, IL-37 levels are increased in patients with hypertension and may be associated with the onset of CAP.

Impact of Helicobacter pylori-Related Metabolic Syndrome Parameters on Arterial Hypertension

“…COX-2 is the principal source of intravascular reactive oxygen species creation, and, in arterial hypertension and diabetes, this seems to be the result of an interaction between COX-2-induced prostaglandins, lower activity of oxidase, RAAS, nicotinamide adenine dinucleotide phosphate, and bone morphogenic protein 4, as a concentrated pathophysiological cascade in stimulating and preserving endothelial dysfunction [155,156]. Moreover, in patients with arterial hypertension, alterations in IL-12, IL-23, IL-27, IL-35, and IL-37 concentrations are connected with the development of carotid atherosclerotic plaque [157,158]. All aforementioned cytokines are also associated with H. pylori infection [159][160][161][162].…”

Developmental endothelial locus-1 in cardiovascular and metabolic diseases: a promising biomarker and therapeutic target

“…Although the pathophysiological mechanisms of hypertension are not fully understood, strong evidences suggest that immune hyperactivation and chronic inflammatory responses play a crucial direct role in the development of hypertension [78]. Our team's previous clinical and animal studies also proved that immune microenvironment disturbances are closely related to hypertension [79][80][81][82][83]. Activated T lymphocytes and pro-inflammatory cytokines such as IL17 are involved in the occurrence and development of angiotensin II (ANGII) and deoxycorticosterone acetate-salt (DOCAsalt)-induced hypertension [84][85][86][87][88][89].…”

The intellectual base and research fronts of IL-37: A bibliometric review of the literature from WoSCC

“…The levels of IL-10 and TGF-b secreted by T cells isolated from patients were decreased in the treatment of rhIL-37 (91). Although the role of IL-37 in the animal model and clinical patients with atherosclerosis (93)(94)(95)(96), acute coronary syndrome (1,97), coronary artery calcification (98), coronary heart disease (99), chronic heart failure (100), atrial fibrillation (101), abdominal aortic aneurysm (102), hypertension (103), and other cardiovascular system diseases (91) has been identified, the timeline view of cocitation clusters revealed that the relationships between IL-37 and the cardiovascular system diseases remain the future hotspots. Cluster #0 seems to be the transfer of the second part of cluster #1 which has been undertaken in terms of research content.…”